Becton Dickinson (NYSE:BDX) announced today that it’s received an FDA emergency use authorization for its COVID-19 antigen test, which the company will start shipping this week.
BD plans to ramp-up manufacturing capacity to 2 million tests per week by the end of September, with 10 million tests produced by the end of September. The tests run on BD’s highly portable Veritor instruments; the company already has about 25,000 Veritor instruments installed at healthcare providers and pharmacies across the U.S.
The assay can produce results in 15 minutes, with 84% sensitivity (ability to exclude false negatives) and 100% specificity (ability to exclude false positives).
Get the full story on our sister site Drug Discovery & Development.